Drug Discovery

Verona Pharma announces new collaborations to develop dry powder and MDI formulations for COPD

Verona Pharma has announced new collaborations with two European technology companies to develop its first-in-class product candidate RPL554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for maintenance treatment of chronic obstructive pulmonary disease (COPD).

Immuno-oncology company Agenus to cut 50 jobs in reorganization

Clinical-stage immuno-oncology firm Agenus is reorganizing its business and operations to straighten its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program.

Warp Drive Bio forms technology alliance with GSK

Warp Drive Bio has partnered with GSK to discover potential therapeutics in oncology and other diseases.

University of Dundee secures grant to discover new antibacterial drugs

University of Dundee in the UK has been awarded almost £1m to boost efforts to identify new new antibiotics to tackle bacterial infections.

PureTech signs licensing and equity deal with Novartis to advance clinical stage mTORC1 programs

PureTech Health has signed a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.

BioLineRx acquires UK cancer immunotherapeutics company Agalimmune

Clinical-stage biopharmaceutical firm BioLineRx has purchased Agalimmune, a private UK-based company with an anti-cancer immunotherapy platform.

GSK, Regeneron to mine gene data from 500000 volunteer participants in UK

Regeneron Pharmaceuticals announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource.

SalvaRx to invest in Rift Biotherapeutics

SalvaRx, a subsidiary of SalvaRx Group, has agreed to invest in Delaware-based biotechnology company Rift Biotherapeutics which focuses on the development of antibodies for use in oncology.

Cell Medica raises £60m to advance multiple cancer programmes

Cellular immunotherapy company, Cell Medica has secured £60m in a Series C financing round with participation from existing investors Touchstone Innovations, funds managed by Woodford Investment Management, and funds managed by Invesco Perpetual.